NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT), a clinical stage life science company, announced it has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements. The company received official notification from The Nasdaq Stock Market LLC confirming this compliance, ensuring that its securities will continue to be listed and traded on the market. Additionally, a Discretionary Panel Monitor will oversee Conduit's compliance for one year starting May 15, 2025, to ensure adherence to Nasdaq's continued listing standards. Conduit retains the right to request a hearing if further compliance issues arise.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.